Corifollitropin alfa
As of the edition of 20 October 2026, Corifollitropin alfa is a protein: marketed, first approved in 2010 (EU); acts on FSHR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Protein
- Brand name
- Elonva
- First approved
- 25 January 2010 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Organon
- Registered trials
- 51, 4 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Inherited and neonatal; Hormones; Cancer; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FSHR | Follicle-stimulating hormone receptor | P23945 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 17 | 15 | 1 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 8 | 7 | 0 | 1 |
| Phase 3 | 12 | 11 | 0 | 1 |
| Phase 4 | 13 | 7 | 1 | 2 |
| All trials | 51 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Organon | Applicant and Lead sponsor of trials | 2000 to now |